DJ-1 in endometrial cancer a possible biomarker to improve differential diagnosis between subtypes

International Journal of Gynecological Cancer

Volumn 24, Issue 4, 2014, Pages 649-658

  Morelli, Michele ^a   Scumaci, Domenica ^a   Di Cello, Annalisa ^a   Venturella, Roberta ^a   Donato, Giuseppe ^a   Faniello, Maria Concetta ^a   Quaresima, Barbara ^a   Cuda, Giovanni ^a   Zullo, Fulvio ^a   Costanzo, Francesco ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

ANXA2 shorter isoform; DJ 1; Endometrial cancer; Immunohistochemical profile; Subtype specific diagnosis

Indexed keywords

BIOLOGICAL MARKER; CALRETICULIN; DJ 1 PROTEIN; ISOENZYME; LIPOCORTIN 2; UBIQUITIN THIOLESTERASE; ONCOPROTEIN; PARK7 PROTEIN, HUMAN; SIGNAL PEPTIDE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MIDDLE AGED; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TWO DIMENSIONAL ELECTROPHORESIS; VERY ELDERLY; WESTERN BLOTTING; ADENOCARCINOMA, CLEAR CELL; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; CLASSIFICATION; COMPARATIVE STUDY; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; PROGNOSIS;

ADENOCARCINOMA, CLEAR CELL; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ONCOGENE PROTEINS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84900384300     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000102     Document Type: Article

References (31)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2010: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
2. Salvesen HB, Akslen LA. Molecular pathogenesis and prognostic factors in endometrial carcinoma. APMIS. 2002;110:673-689.
3. Stewart CJ, Crook ML, Leung YC, et al. Expression of cell cycle regulatory proteins in endometrial adenocarcinoma: variations in conventional tumor areas and in microcystic elongated and fragmented glands. Mod Pathol. 2009;22:725-733.
4. Kurman RJ, Visvanathan K, Shih IeM. Bokhman's dualistic model of endometrial carcinoma. Revisited. Gynecol Oncol. 2013;129:271-272.
5. Clarke BA, Gilks CB. Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. J Clin Pathol. 2010;63:410-415.
6. Cancer Genome Atlas Research Network, Kandoth C Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67-73.
7. Darvishian F, Hummer AJ, Thaler HT, et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol. 2004;28:1568-1578.
8. Kumar S, Medeiros F, Dowdy SC, et al. A prospective assessment of the reliability of frozen section to direct intraoperative decision making in endometrial cancer. Gynecol Oncol. 2012;127:525-531.
9. Le Naour F, Misek DE, Krause MC, et al. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res. 2001;7:3328Y3335.
10. Bande MF, Santiago M, Blanco MJ, et al. Serum DJ-1/PARK 7 is a potential biomarker of choroidal nevi transformation. Invest Ophthalmol Vis Sci. 2012;53:62-67.
11. Chen Y, Kang M, Lu W, et al. DJ-1, a novel biomarker and a selected target gene for overcoming chemoresistance in pancreatic cancer. J Cancer Res Clin Oncol. 2012;138: 1463-1474.
12. Shu K, Xiao Z, Long S, et al. Expression of DJ-1 in endometrial cancer: close correlation with clinicopathological features and apoptosis. Int J Gynecol Cancer. 2013;23:1029-1035.
13. Amato R, Scumaci D, D'Antona L, et al. Sgk1 enhances RANBP1 transcript levels and decreases taxol sensitivity in RKO colon carcinoma cells. Oncogene. 2013;32:4572-4578.
14. Sinha P, Poland J, Schnö lzer M, et al. A new silver staining apparatus and procedure for matrix-assisted laser desorption/ionization-time of flight analysis of proteins after two-dimensional electrophoresis. Proteomics. 2001;1:835-840.
15. Gaspari M, Cuda G. Nano LC-MS/MS: a robust setup for proteomic analysis. Methods Mol Biol. 2011;790:115-126.
16. Scumaci D, Gaspari M, Saccomanno M, et al. Assessment of an ad hoc procedure for isolation and characterization of human albuminome. Anal Biochem. 2011;418:161-163.
17. Quaresima B, Romeo F, Faniello MC, et al. The BRCA1 5083 del 19 mutant allele selectively upregulates periostin expression in vitro and in vivo. Clin Cancer Res. 2008;14:6797-6803.
18. Kim RH, Peters M, Jang Y, et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell. 2005;7:263-273.
19. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009;4:127-150.
20. Zody MC, Garber M, Sharpe T, et al. Analysis of the DNA sequence and duplication history of human chromosome 15. Nature. 2006;440:671-675.
21. Maxwell GL, Hood BL, Day R, et al. Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammation. Gynecol Oncol. 2011;121:586-594.
22. MacKeigan JP, Clements CM, Lich JD, et al. Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIalpha. Cancer Res. 2003;63:6928-6934.
23. Rai P, Shivaji S. The role of DJ-1 in the pathogenesis of endometriosis. PLoS One. 2011;6:e18074.
24. Köbel M, Kalloger SE, Baker PM, et al. Diagnosis of ovarian carcinoma cell type is highly reproducible: a trans-Canadian study. Am J Surg Pathol. 2010;34:984-993.
25. Anglesio MS, Carey MS, Köbel M, et al. Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol. 2011;121:407-415.
26. Reid-Nicholson M, Iyengar P, Hummer AJ, et al. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol. 2006;19: 1091-1100.
27. Alkushi A, Köbel M, Kalloger SE, et al. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int J Gynecol Pathol. 2010;29:343-350.
28. Kumar S, Mariani A, Bakkum-Gamez JN, et al. Risk factors that mitigate the role of paraaortic lymphadenectomy in uterine endometrioid cancer. Gynecol Oncol. 2013;130:441-445.
29. del Carmen MG, Birrer M, Schorge JO. Uterine papillary serous cancer: a review of the literature. Gynecol Oncol. 2012;127:651-661.
30. Fader AN, Starks D, Gehrig PA, et al. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 2009;115:244-248.
31. Kumar S, Bandyopadhyay S, Semaan A, et al. The role of frozen section in surgical staging of low risk endometrial cancer. PLoS One. 2011;6:e21912.